Carlos de Lima, MD, stopped by the Blood Cancers Today video booth at the 2022 SOHO Annual Meeting and gave some advice on how to build a chimeric antigen receptor (CAR)-T program.
How to Build Your CAR-T Program with Carlos de Lima, MD
By Leah Sherwood - Last Updated: November 16, 2022Related Posts
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Risk factors for infection and infection-related mortality were assessed in recipients of CD19 CAR T-cell therapy.
The phase 1 ALPHA2/ALPHA studies demonstrate cema-cel's safety and efficacy in relapsed LBCL.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Liso-cel outperforms standard care in second-line LBCL, showing 29.5-month EFS vs 2.4 months in TRANSFORM trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.